Claim Ledger
29% answered
Did management answer the analysts?
12 analyst questions audited, 6 evaded or deflected.
View Claim Ledger →
Divi's Laboratories — Q3 FY25
Divis Laboratories reported a strong Q3 FY25 with PAT of INR 589 crore, up 64.5% YoY, driven by robust custom synthesis growth and stable generics volumes.
bullish
medium
✓ Verified against BSE filing
2-Minute Summary
✦ AI-Generated from Full Transcript
Divis Laboratories reported a strong Q3 FY25 with PAT of INR 589 crore, up 64.5% YoY, driven by robust custom synthesis growth and stable generics volumes. The company commissioned Phase I of its Kakinada Unit 3 in January 2025, enhancing backward integration and freeing capacity at existing units. Management highlighted increased customer engagement, RFPs, and new opportunities in GLP-1 peptides and contrast media. Guidance points to sustained double-digit revenue growth, though margin trajectory remains uncertain due to product mix and Kakinada ramp-up costs. Key risks include potential US tariff policy changes and ongoing pricing pressure in generics.
डिविस लैबोरेटरीज ने वित्त वर्ष 2025 की तीसरी तिमाही में शानदार प्रदर्शन किया। कंपनी का मुनाफा 589 करोड़ रुपये रहा, जो पिछले साल की तुलना में 64.5% ज्यादा है। यह वृद्धि कस्टम सिंथेसिस (ग्राहकों के लिए खास रसायन बनाना) और जेनेरिक दवाओं (सस्ती दवाइयां) की स्थिर बिक्री से हुई। जनवरी 2025 में काकीनाडा यूनिट 3 का पहला चरण शुरू हुआ, जिससे उत्पादन लागत कम होगी और मौजूदा यूनिट्स पर दबाव घटेगा। कंपनी को GLP-1 पेप्टाइड्स (डायबिटीज और वजन घटाने की दवा) और कंट्रास्ट मीडिया (स्कैन में इस्तेमाल होने वाले पदार्थ) में नए अवसर मिल रहे हैं। आगे राजस्व में दो अंकों की वृद्धि की उम्मीद है, लेकिन मुनाफा उत्पाद मिश्रण और नई यूनिट की लागत पर निर्भर करेगा। जोखिमों में अमेरिकी टैरिफ नीति और जेनेरिक दवाओं पर कीमत दबाव शामिल है।
Promises0 met · 1 missedRisks4 trackedTranscriptfull text
Research workspace
Focused Modules
Promises
1 promise
Promise Tracker
0 delivered, 0 close, 1 missed.
View Promises →
Risks
4 risks
Risk Intelligence
US tariff policy changes
View Risks →
Transcript
Full text
Call Transcript
Full transcript text is available on this route.
Read Transcript →Quarter Snapshot
Custom Synthesis Revenue Share (Q3)
53%
+1pp YoY
Custom synthesis contributed 53% of total revenue in Q3, up from 52% in the nine-month period, reflecting strong demand.
Nutraceuticals Revenue (9M)
INR 576 crore
+12% YoY
Nutraceuticals segment grew steadily, with Q3 revenue of INR 170 crore, supported by new product introductions.
Capacity Utilization (Unit 1 & 2)
80%
flat YoY
Utilization remains at 80%, with Kakinada freeing up capacity for new projects and regulatory products.
Exports to Europe & US (9M)
72%
flat YoY
Exports to Europe and US remained stable at 72% of total sales, with overall exports at 87%.
What Changed vs Last Quarter
NEW
Double-digit revenue growth target
Management targets double-digit revenue growth on a yearly basis, driven by custom synthesis and generics.
NEW
Kakinada Phase I full commissioning in 6 months
The remaining part of Phase I at Kakinada is expected to be operational in about six months.
NEW
Generics and custom synthesis to be 50-50%
The company aims for a balanced revenue mix of 50% generics and 50% custom synthesis over time.
DROPPED
Unit 3 commercial production to start December 2024
Phase-wise production at the 200-acre greenfield Kakinada facility will begin in December 2024, initially focusing on backward integration and regulatory qualifications.
DROPPED
Contrast media volume growth of 20-30% YoY
Management expects year-on-year volume increase of 20-30% in contrast media, driven by long-term contracts and new qualifications.
DROPPED
New generic launches from 2026 onwards
Multiple generic products are advancing towards customer qualifications and regulatory approvals, with revenue contributions expected from 2026.
DROPPED
FY25 total CapEx of ~INR 1,600 Cr
Total capital expenditure for FY25, including Kakinada, is expected to be around INR 1,600 crores, with INR 1,000 crores remaining to be spent.
NEW RISK
US tariff policy changes
Potential changes in US trade policies could impact export competitiveness, though management noted no immediate tariffs on India.
NEW RISK
Kakinada ramp-up costs
Initial operational expenses at the new Kakinada facility may temporarily pressure margins until full utilization is achieved.
RISK GONE
Raw material cost volatility
While raw material prices have stabilized, they remain sensitive to Middle East developments and crude oil fluctuations, posing a risk to margins.
RISK GONE
Unit 3 ramp-up and regulatory approvals
The greenfield Unit 3 will take time to achieve regulatory approvals and full utilization, with initial production focused on non-regulatory products.
🤫 Topics management stopped discussing
Mentioned in Q1 FY25, Q2 FY24, Q2 FY25, Q3 FY24
Phase-wise production at the 200-acre greenfield Kakinada facility will begin in December 2024, initially focusing on backward integration and regulatory qualifications.
Mentioned in Q1 FY24, Q1 FY25
While BIOSECURE Act opportunities are emerging, the timing and conversion of phase II/III molecules into commercial revenue remain uncertain and may take years.
Mentioned in Q1 FY25, Q2 FY25
Total capital expenditure for FY25, including Kakinada, is expected to be around INR 1,600 crores, with INR 1,000 crores remaining to be spent.
Mentioned in Q1 FY24, Q2 FY25
While raw material prices have stabilized, they remain sensitive to Middle East developments and crude oil fluctuations, posing a risk to margins.
Fast read
Guidance and risk preview
Management targets double-digit revenue growth on a yearly basis, driven by custom synthesis and generics.
Potential changes in US trade policies could impact export competitiveness, though management noted no immediate tariffs on India.
View Risks →